CollPlant Biotechnologies (CLGN) Expected to Announce Earnings on Thursday

CollPlant Biotechnologies (NASDAQ:CLGN) will likely be issuing its Q4 2025 results before the market opens on Thursday, April 2nd. Analysts expect CollPlant Biotechnologies to post earnings of ($0.19) per share and revenue of $6.7750 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 9:30 AM ET.

CollPlant Biotechnologies Trading Up 5.5%

Shares of NASDAQ CLGN opened at $0.75 on Thursday. The firm has a market cap of $9.60 million, a P/E ratio of -0.74 and a beta of 3.02. The business’s 50 day moving average is $0.96 and its 200-day moving average is $1.70. CollPlant Biotechnologies has a 1-year low of $0.50 and a 1-year high of $4.98.

Analysts Set New Price Targets

Several research firms recently commented on CLGN. Weiss Ratings reiterated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Wednesday, January 21st. D. Boral Capital cut shares of CollPlant Biotechnologies from a “buy” rating to a “hold” rating in a research report on Friday, February 6th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.